Jae-Sung Yu
Overview
Explore the profile of Jae-Sung Yu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1244
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu J, Liao H, Pritchett J, Bowman C, Vivian C, Parks R, et al.
J Virol Methods
. 2017 Aug;
249:85-93.
PMID: 28837840
Development of a HIV-1 vaccine is a major global priority. The yellow fever virus (YFV) attenuated vaccine 17D is among the most effective of currently used vaccines. However, the stability...
2.
Pardi N, Hogan M, Pelc R, Muramatsu H, Andersen H, DeMaso C, et al.
Nature
. 2017 Feb;
543(7644):248-251.
PMID: 28151488
Zika virus (ZIKV) has recently emerged as a pandemic associated with severe neuropathology in newborns and adults. There are no ZIKV-specific treatments or preventatives. Therefore, the development of a safe...
3.
Zhang R, Alam S, Yu J, Scearce R, Lockwood B, Hwang K, et al.
Monoclon Antib Immunodiagn Immunother
. 2016 Jul;
35(4):217-26.
PMID: 27386924
Immunoglobulin A (IgA) antibodies exist in monomeric, dimeric, and secretory forms. Dimerization of IgA depends on a 15-kD polypeptide termed "joining (J) chain," which is also part of the binding...
4.
Williams W, Liao H, Moody M, Kepler T, Alam S, Gao F, et al.
Science
. 2015 Aug;
349(6249):aab1253.
PMID: 26229114
An HIV-1 DNA prime vaccine, with a recombinant adenovirus type 5 (rAd5) boost, failed to protect from HIV-1 acquisition. We studied the nature of the vaccine-induced antibody (Ab) response to...
5.
Kepler T, Munshaw S, Wiehe K, Zhang R, Yu J, Woods C, et al.
Front Immunol
. 2014 May;
5:170.
PMID: 24795717
Affinity maturation of the antibody response is a fundamental process in adaptive immunity during which B-cells activated by infection or vaccination undergo rapid proliferation accompanied by the acquisition of point...
6.
Taylor N, Bahunde F, Thompson A, Yu J, Jacobs Jr W, Letvin N, et al.
Clin Vaccine Immunol
. 2012 Jul;
19(9):1416-25.
PMID: 22787192
Mycobacteria have features that make them attractive as potential vaccine vectors. The nonpathogenic and rapidly growing Mycobacterium smegmatis can express both Mycobacterium tuberculosis antigens and heterologous antigens from other pathogens,...
7.
Moody M, Yates N, Amos J, Drinker M, Eudailey J, Gurley T, et al.
J Virol
. 2012 May;
86(14):7496-507.
PMID: 22553329
Most antibodies that broadly neutralize HIV-1 are highly somatically mutated in antibody clonal lineages that persist over time. Here, we describe the analysis of human antibodies induced during an HIV-1...
8.
Moody M, Zhang R, Walter E, Woods C, Ginsburg G, McClain M, et al.
PLoS One
. 2011 Nov;
6(10):e25797.
PMID: 22039424
Background: During the recent H1N1 influenza pandemic, excess morbidity and mortality was seen in young but not older adults suggesting that prior infection with influenza strains may have protected older...
9.
Liao H, Chen X, Munshaw S, Zhang R, Marshall D, Vandergrift N, et al.
J Exp Med
. 2011 Oct;
208(11):2237-49.
PMID: 21987658
The initial antibody response to HIV-1 is targeted to envelope (Env) gp41, and is nonneutralizing and ineffective in controlling viremia. To understand the origins and characteristics of gp41-binding antibodies produced...
10.
Gray E, Moody M, Wibmer C, Chen X, Marshall D, Amos J, et al.
J Virol
. 2011 May;
85(15):7719-29.
PMID: 21613396
The C3-V4 region is a major target of autologous neutralizing antibodies in HIV-1 subtype C infection. We previously identified a Center for AIDS Program of Research in South Africa (CAPRISA)...